Synovial Sarcoma

Watchlist

(log in to enable)

Retrieved

2022-04-26

Source

Gard

Trials

—

Genes

SSX1, SSX2, SS18, BCL2, SHCBP1, VIM, TLE1, SYT1, CD38, SSX2B, SMARCB1, CTAG1A, CTNNB1, CTAG1B, TP53, ERBB2, EWSR1, KIT, CD99, EGFR, FZD10, SSX4, CD34, CCND1, BCOR, PROM1, CTSS, IGF2, MET, PDGFRA

SSX1, SSX2, SS18, BCL2, SHCBP1, VIM, TLE1, SYT1, CD38, SSX2B, SMARCB1, CTAG1A, CTNNB1, CTAG1B, TP53, ERBB2, EWSR1, KIT, CD99, EGFR, FZD10, SSX4, CD34, CCND1, BCOR, PROM1, CTSS, IGF2, MET, PDGFRA, TNF, EZH2, HEATR3, SS18L1, CDKN2A, VEGFA, IGF1R, IGF1, IL1B, MDM2, FOXM1, MMP2, MUC1, SOX2, HGF, STAT3, CDH1, PAX8, PRKAR1A, SPG7, CXCL12, SALL2, TGFB1, SOX10, IL17A, MAPK3, RASSF1, MAPK1, HPSE, TNFSF13B, BANF1, NME1, CXCR4, ABCB1, TRIM13, PAX3, OAT, NR1I3, PRAME, MKI67, YBX1, HDAC9, MMP9, ABCC1, VCAM1, H3P10, IL10, CD274, CRK, ATF2, CXADR, ELF3, ANKRD36B, CASR, ZNF654, F5, MIR206, CXADRP1, ETFA, HBA2, ARR3, HBG1, PWWP3B, MIR145, MIR10B, ERVW-4, GDF6, KLHL34, FRMPD2, EZR, STAT6, KCNH8, MIR761, AIMP2, NR4A3, SRC, MLLT10, LOC110806263, HMGA2, CCNB3, MIR155, SYCP1, TRBV20OR9-2, MIR92B, SYP, MIR495, ADAM17, TAGLN, TAP1, TAZ, TFPI, TLR3, MIR183, FRMPD2B, CDR3, DUX4, THAS, THBD, MIR17, HBHR, RNF19A, NCOA3, SSX3, CIB1, CXCL13, AHSA1, DYM, NES, NANS, FXYD5, PIAS4, SS18L2, PUF60, FLVCR1, SIRT2, PPRC1, CIC, NUPR1, SIRT1, POLDIP2, KCNH4, NGDN, MSLN, SLC12A9, KDM2B, KIDINS220, AXIN2, TNFSF13, SMUG1, LBH, VTCN1, BRD9, RASAL3, MBD2, USP6, REPS2, TSPYL2, VAMP3, ADIPOQ, GRAP2, PRM3, PDZD4, PIEZO1, MIB1, GINS1, SNAP23, ALB, SNAI1, ELK1, EP300, EPHB2, ERCC5, ERG, ESR1, F2, F2RL1, FGFR2, FOXO1, FOLH1, GAB1, GLB1, GLO1, GSK3B, HBA1, HBB, HBG2, HLA-A, HLA-C, HMGA1, ICAM1, IFNG, IL1A, IL5, IL6, CXCL8, IDO1, ENO2, EGR1, SMN2, DUSP6, ALK, APC, AQP8, FASLG, AQP5, AQP9, ATR, ATRX, BCL6, BCR, CFB, BIK, BMP6, CAV1, CD68, CDK4, CDK9, CDKN1A, CDKN1B, CDKN3, CLDN7, CRABP1, MAPK14, CSK, CTLA4, ACE, DECR1, INHA, ITGB2, KRT7, KRT19, PIK3CG, PLK1, PLS3, PMCH, MED1, MAPK8, ALDH1A1, PTEN, PTGS2, PTN, PTPN1, RAC1, RAD23B, RBBP8, RBP4, RPL34, S100A4, SAI1, TSPAN31, CX3CL1, SELE, SLC3A1, SLC6A4, SLC12A3, SMARCA1, SMARCA2, SMN1, PIK3CD, PIK3CB, PIK3CA, MSH3, LBR, MAGEA1, MAGEA4, MB, MCM7, MDK, MDM4, MIF, CXCL9, MLH1, MMP3, MMP14, MTHFR, PDGFRB, MUC4, MYCN, NEDD4, NFKB1, NKX2-2, TBC1D25, PAEP, PAX2, PAX7, PC, PCNA, PDCD1, MAP2K7

Drugs

(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione, (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) diamidophosphate, 16-base single-stranded peptide nucleic acid oligonucleotide linked to a 7-amino acid peptide, 18-(p-(, 4-oxo-4H-chromene-2-carboxylic acid (2-(2-4-(2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-ethyl)-phenyl-2H-tetrazol-5-yl)-4,5-dimethoxy-phenyl)-amide, 7-ethyl-10-hydroxy-camptothecin, Anlotinib, Autologous CD4+ and CD8+ T cells transduced with a lentiviral vector encoding an affinity enhanced T cell receptor specific to MAGE-A4, Autologous CD4+ and CD8+ T cells transduced with lentiviral vector containing an affinity-enhanced T-cell receptor targeting the New York esophageal antigen-1, Brostallicin, Camsirubicin, Crenolanib besylate, Deforolimus, Doxorubicin hydrochloride (liposomal) ( DOXIL ), Doxorubicin(6-maleimidocaproyl)hydrazone, Fenretinide, Fibromun, Genetically modified serotype 5/3 adenovirus coding for granulocyte-macrophage colony-stimulating factor, Glucopyranosyl lipid A stable emulsion and recombinant New York oesophageal squamous cell carcinoma-1 protein (NY-ESO-1), Human/murine chimeric monoclonal antibody against endoglin, Ifosfamide ( HOLOXAN, IFEX ), Larotrectinib ( VITRAKVI ), Mammalian target of rapamcyin (mTOR) inhibitor, N-acetylsarcosyl-glycyl-L-valyl-D-allo-isoleucyl-L-threonyl-L-norvalyl-L-isoleucyl-L-arginyl-L-prolyl-N-ethylamide, Olaratumab ( LARTRUVO ), Ombrabulin, Paclitaxel ( TAXOL ), Palifosfamide, Propranolol hydrochloride ( HEMANGEOL ), Sindbis virus envelope pseudotyped lentiviral vector encoding New York oesophageal squamous cell carcinoma-1 protein, Trabectedin ( YONDELIS ), Vinorelbine tartrate, Yttrium (90Y)-DTPA-radiolabelled chimeric monoclonal antibody against frizzled homologue 10

Interested in hearing about new therapies?

Synovial sarcoma is a rare and aggressive soft tissue sarcoma. In the early stages of the condition, it may cause no noticeable signs or symptoms. However, as the tumor grows larger, affected people may notice a lump or swelling. In some cases, the tumor can limit range of motion or cause numbness and/or pain if it presses on nearby nerves. Although synovial sarcoma does not have a clearly defined cause, genetic factors are believed to influence the development of this disease. Cells in these tumors are usually characterized by the presence of a translocation involving chromosomes X and 18. This translocation is specific to synovial sarcoma and is often used to diagnose the condition. Treatment generally includes a combination of surgery, radiation therapy and/or chemotherapy.